CRISPR Base Editing: How Base Editors Work and Why They Beat Standard Cas9

You've probably heard of CRISPR as the gene-editing technology that cuts DNA. Scientists use it to delete genes, modify them, insert new sequences. In 2020, its inventors won the Nobel Prize. By 2023, the first CRISPR therapy was approved by the FDA. The technology changed biology. But here's the thing: cutting DNA is a blunt instrument. And the next generation of gene editing doesn't cut anything at all.

*Think about it this way.* Your genome is a text document three billion letters long. Standard CRISPR-Cas9 is a pair of scissors. It finds the sentence you want to fix and cuts it in two, hoping the cell repairs the break in a way that produces your desired result. But cuts don't always heal cleanly. Sometimes the repair introduces extra letters, sometimes it deletes some. For reading a gene out of existence, that's fine. For correcting a single-letter typo — changing one A to a G — you need something more like a pencil with an eraser.

## What's actually wrong with cutting DNA

**CRISPR-Cas9** works by coupling a guide RNA (which finds the target sequence) with the Cas9 enzyme (which cuts both strands of the DNA double helix). The cut creates what's called a double-strand break. Cells have two main repair pathways for double-strand breaks.

*Non-homologous end joining* (NHEJ) is the quick and messy one. The cell stitches the ends back together, but the process often introduces small insertions or deletions — *indels* — at the cut site. This effectively disrupts the gene. Useful if you want to knock out a gene entirely. Terrible if you want to make a precise single-letter correction.

*Homology-directed repair* (HDR) can incorporate a provided template to make precise edits, but it only operates during cell division, works inefficiently in most cell types, and introduces its own off-target errors.

For the roughly 70,000 human diseases caused by single-nucleotide mutations — a single wrong letter in the genome — standard CRISPR-Cas9 is the wrong tool.

## How base editors work

**Base editing**, pioneered by David Liu's laboratory at Harvard in 2016, solves this differently. Instead of cutting DNA, a base editor chemically converts one DNA base to another — without breaking either strand of the double helix.

Here's the mechanism. Liu fused a deactivated Cas9 (called dCas9, or more precisely nCas9 which only nicks one strand) to an enzyme called a deaminase. The dCas9 still finds the target sequence via the guide RNA and binds to it, causing a small bubble of single-stranded DNA to form. The deaminase then chemically modifies a specific base in that single-stranded bubble.

The first type developed were *cytosine base editors* (CBEs). A deaminase enzyme converts cytosine (C) to uracil (U), which the cell reads as thymine (T). Net result: C→T change, with the complement on the other strand changing from G→A. This enables correction of mutations like the ones causing certain forms of cancer, progeria (premature aging), and some metabolic diseases.

*Adenine base editors* (ABEs) came next, in 2017. These use an evolved enzyme to convert adenine (A) to inosine (I), which the cell reads as guanine (G). Net result: A→G change. Together, CBEs and ABEs can make four of the twelve possible point-mutation corrections at high efficiency.

> 🔬 **Quick experiment:** Pick any three-letter English word. Now change one letter to produce a different word. You've done conceptually what a base editor does: found a specific "word" in the genome and changed one letter. The challenge in biology is that the genome contains three billion letters, and the editor must find exactly the right one without changing any of the others.

## Prime editing: the search-and-replace upgrade

Even base editing has limits. You can only install the four corrections that CBEs and ABEs handle (C→T, G→A, A→G, T→C), and you can't insert or delete sequences. In 2019, Liu's group published *prime editing* — described in the paper as a "versatile and precise genome editing method."

Prime editing uses a modified Cas9 fused to a reverse transcriptase enzyme, guided by a redesigned RNA called a prime editing guide RNA (pegRNA). The pegRNA contains both the target-finding sequence and the desired edit, encoded as an RNA template. The reverse transcriptase reads this template and synthesizes a new DNA sequence incorporating the desired change, which then gets incorporated into the genome.

In theory, prime editing can make all 12 types of point mutations, plus small insertions and deletions. Think about it this way: if base editors are a pencil with an eraser that can only write specific letters, prime editors are a word processor's find-and-replace function — you specify both what you're looking for and exactly what you want it to say.

## Why this matters clinically

The diseases amenable to base editing are not rare edge cases. Sickle cell disease is caused by a single A→T mutation in the gene for hemoglobin — one wrong letter out of three billion. The original CRISPR-based therapy approved in 2023 (Casgevy) works not by correcting this mutation directly but by reactivating a fetal form of hemoglobin that the mutation doesn't affect. Base editing could, in principle, fix the mutation directly.

*Progeria*, the accelerated aging disease, is caused by a C→T point mutation. Base editing in the relevant cells has been shown to extend lifespan in mouse models. A clinical trial began in 2023.

Certain inherited forms of high cholesterol, caused by mutations in the gene PCSK9, are amenable to base-editing approaches that could provide a single-dose treatment where patients currently take daily medication.

The broader implication is statistical. An estimated 58% of known pathogenic point mutations in the human genome are the types that CBEs or ABEs can correct. That's a large fraction of the genetic disease landscape.

## What base editing still can't do

Off-target editing — making changes at the wrong genomic location — remains a concern, though base editors produce fewer off-targets than standard CRISPR for the mutations they can correct. Large insertions or deletions, rearrangements, complex multi-gene interactions — these remain beyond current base-editing approaches.

Delivery is the other unsolved problem. Getting base editors into relevant cells, particularly inside the body rather than in laboratory dishes, requires vehicles like lipid nanoparticles or viral vectors, each with their own safety and efficiency tradeoffs.

But the direction is unmistakable. **CRISPR-Cas9** opened a door. Base editing and prime editing are walking through it more carefully, making changes precise enough to treat diseases that scissors couldn't reach. The intuitive answer to "how do you fix a single-letter mutation?" turns out to be: don't cut — just change the letter.

CRISPR Base Editing: How Base Editors Work and Why They Beat Standard Cas9

// COMMENTS

ON THIS PAGE